Items where Author is "Protheroe, A"

Article

James, N and de Bono, J and Spears, M and Clarke, NW and Mason, M and Dearnaley, D and Ritchie, A and Amos, C and Gilson, C and Jones, R and Matheson, DJ and Millman, R and Attard, G and Chowdhury, S and Cross, W and Gillessen, S and Parker, C and Russell, M and Berthold, D and Brawley, C and Adab, F and Aung, S and Birtle, AJ and Bowen, J and Brock, S and Chakraborti, P and Ferguson, C and Gale, J and Gray, E and Hingorani, M and Hoskin, P and Lester, J and Malik, Z and McKinna, F and McPhail, N and Money-Kyrle, J and O'Sullivan, J and Parikh, O and Protheroe, A and Robinson, A and Srihari, N and Thomas, C and Wagstaff, J and Wylie, J and Zarkar, A and Parmar, M and Sydes, M (2017) Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. The New England journal of medicine, 377 (4). pp. 338-351. ISSN 0028-4793 DOI: https://doi.org/10.1056/NEJMoa1702900

Mason, M and Clarke, NW and James, N and Dearnaley, D and Spears, M and Ritchie, A and Attard, G and Cross, W and Jones, R and Parker, C and Russell, J and Thalmann, G and Schiavone, F and Cassoly, E and Matheson, DJ and Millman, R and Rentsch, C and Barber, J and Gilson, C and Ibrahim, A and Logue, J and Lydon, A and Nikapota, A and O'Sullivan, J and Porfiri, E and Protheroe, A and Srihari, N and Tsang, D and Wagstaff, J and Wallace, J and Walmsley, C and Parmar, M and Sydes, M (2017) Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology, 35 (14). ISSN 0732-183X DOI: https://doi.org/10.1200/JCO.2016.69.0677

James, ND and Sydes, MR and Clarke, NW and Mason, MD and Dearnaley, DP and Spears, MR and Ritchie, AWS and Parker, CC and Russell, JM and Attard, G and De Bono, J and Cross, W and Jones, RJ and Thalmann, G and Amos, C and Matheson, D and Millman, R and Alzouebi, M and Beesley, S and Birtle, AJ and Brock, S and Cathomas, R and Chakraborti, P and Chowdhury, S and Cook, A and Elliott, T and Gale, J and Gibbs, S and Graham, JD and Hetherington, J and Hughes, R and Laing, R and McKinna, F and McLaren, DB and O'Sullivan, JM and Parikh, O and Peedell, C and Protheroe, A and Robinson, AJ and Srihari, N and Srinivasan, R and Staffurth, J and Sundar, S and Tolan, S and Tsang, D and Wagstaff, J and Parmar, MKB (2015) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet, 387 (10024). 1163 - 1177. ISSN 0140-6736 DOI: https://doi.org/10.1016/S0140-6736(15)01037-5